LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Proline-Specific Peptidase Activities in Plasma of Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 16 Mar 2022

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can elicit a protracted pneumonitis, but also kidney, cardiovascular and neurological complications and thromboembolic phenomena of unclear pathogenesis.

These COVID-19 patients experience several features of dysregulated immune system observed in sepsis. The activity of proline-specific peptidases in plasma of COVID-19 hospitalized patients has been investigated. The peptidases studied were dipeptidyl peptidase 4 (DPP4), fibroblast activation protein alpha (FAP), prolyl oligopeptidase (PREP) and prolylcarboxpeptidase (PRCP).


Image: The HPLC model: LC-2050 series, three types of detector setup (UV, PDA, detector-less) are available to suit any analysis methods and aims (Photo courtesy of Shimadzu)
Image: The HPLC model: LC-2050 series, three types of detector setup (UV, PDA, detector-less) are available to suit any analysis methods and aims (Photo courtesy of Shimadzu)

Medical Biochemists at the University of Antwerp (Antwerp, Belgium) and their colleagues collected heparin plasma samples from 56 hospitalized patients with laboratory-confirmed (PCR test) COVID-19 shortly after hospital admission (=baseline, 1 to 5 days after hospital admission) and thereafter at irregular time points until discharge. Additionally, plasma was taken from a control group of 32 healthy volunteers.

The scientists measured DPP4 activity colorimetrically using the substrate Gly-Pro-pNA. FAP and PREP activity was measured fluorometrically using Z-Gly-Pro-AMC in a combined FAP/PREP assay. PRCP activity was determined by measuring the hydrolysis of Z-Pro-Phe by use of a reversed-phase high-performance liquid chromatography technique. The enzymatically formed Z-Pro was tracked by its UV absorbance at 210 nm after separation on a Shimadzu HPLC apparatus (Kyoto, Japan).

The investigators reported that compared to healthy controls, both DPP4 and FAP activities were significantly lower in COVID-19 patients at hospital admission and FAP activity further decreased significantly in the first week of hospitalization. While PRCP activity remained unchanged, PREP activity was significantly increased in COVID-19 patients at hospitalization and further increased during hospital stay and stayed elevated until the day of discharge.

The authors concluded that a similar pattern in the proline-specific peptidase activities in COVID-19 patients compared with patients experiencing septic shock: decreased DPP4 and FAP activity and elevated PREP activity. The study was published on March 10, 2022 in the journal Clinica Chimica Acta.

Related Links:
University of Antwerp 
Shimadzu 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Portable POCT Blood Gas Analyzer
BD100

Latest Clinical Chem. News

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
16 Mar 2022  |   Clinical Chem.

FDA Clears Roche Blood Test for Alzheimer’s Amyloid Pathology Assessment
16 Mar 2022  |   Clinical Chem.

Blood Test Markers Could Help Identify Older Adults at Risk of Disability
16 Mar 2022  |   Clinical Chem.